Last updated: November 8, 2026
IQIRVO (elafibranor) is an Ipsen commercial product for primary biliary cholangitis (PBC), approved by the FDA in June 2024 under the accelerated-approval pathway. Its commercial opportunity depends on uptake among patients inadequately controlled by ursodeoxycholic acid (UDCA), competition from Livdelzi (seladelpar), the withdrawal of Ocaliva (obeticholic acid), and conversion of accelerated approval into full approval. Ipsen does not report IQIRVO as a standalone revenue line, so the product’s financial trajectory must be assessed through launch timing, market access, label breadth, milestone obligations, and competitive positioning.
What is IQIRVO approved to treat?
IQIRVO is approved for adults with PBC in combination with UDCA when the patient has an inadequate response to UDCA, or as monotherapy for patients unable to tolerate UDCA. The FDA approval is accelerated and is based on biochemical improvement, primarily alkaline phosphatase (ALP) response at 52 weeks. Clinical benefit has not been confirmed.[1]
| Product |
Active ingredient |
Sponsor |
FDA approval |
Indication |
| IQIRVO |
Elafibranor |
Ipsen |
June 10, 2024 |
PBC with inadequate UDCA response or UDCA intolerance |
| Livdelzi |
Seladelpar |
Gilead Sciences |
August 14, 2024 |
PBC with inadequate UDCA response or UDCA intolerance |
| Ocaliva |
Obeticholic acid |
Intercept Pharmaceuticals |
2016; U.S. withdrawal in 2024 |
Former second-line PBC treatment |
| Ursodiol products |
Ursodeoxycholic acid |
Multiple generic manufacturers |
Long-established |
First-line PBC therapy |
IQIRVO is administered orally at 80 mg once daily. The label includes warnings for myopathy and rhabdomyolysis, bone fractures, fetal harm, biliary obstruction, and clinically relevant drug interactions.[1]
How large is the IQIRVO addressable market?
The commercial market is a specialized rare-disease market rather than a mass-market hepatology opportunity. PBC is concentrated in adult women and typically requires long-term treatment. UDCA remains the standard first-line therapy, leaving IQIRVO positioned as a second-line or UDCA-intolerant treatment.
The addressable population can be divided into four segments:
- Patients with an inadequate biochemical response to UDCA.
- Patients who cannot tolerate UDCA.
- Patients previously treated with Ocaliva who require a replacement.
- Patients who remain untreated or undertreated because of access, tolerability, or diagnostic delays.
IQIRVO’s opportunity is constrained by several factors:
- PBC is a rare disease with a limited diagnosed population.
- Treatment decisions depend heavily on ALP levels, bilirubin, liver fibrosis, tolerability, and specialist prescribing.
- IQIRVO is not approved for broad liver disease, metabolic dysfunction-associated steatohepatitis, or nonalcoholic steatohepatitis.
- The accelerated approval is based on a surrogate endpoint rather than demonstrated reduction in transplant or mortality risk.
- Payers may require prior UDCA use and specialist documentation.
The withdrawal of Ocaliva expands the available second-line market, but Livdelzi entered the same segment only two months after IQIRVO. That timing reduces the benefit IQIRVO would otherwise have received from being the only newly approved second-line option.
How effective is IQIRVO compared with Livdelzi?
IQIRVO generated a statistically significant ALP response in its pivotal trial. In the FDA review, 51% of IQIRVO-treated patients achieved the composite biochemical response at 52 weeks compared with 4% of placebo-treated patients.[1]
Livdelzi reported a different trial design and endpoint. In its pivotal study, 61.7% of seladelpar-treated patients achieved the primary biochemical response compared with 20% for placebo.[2] The results cannot be treated as a direct head-to-head comparison because the studies used different populations, background therapy requirements, response definitions, and trial execution.
| Factor |
IQIRVO |
Livdelzi |
| Active ingredient |
Elafibranor |
Seladelpar |
| Sponsor |
Ipsen |
Gilead Sciences |
| FDA approval |
June 2024 |
August 2024 |
| Regulatory pathway |
Accelerated approval |
Accelerated approval |
| Mechanism |
PPAR-alpha and PPAR-delta agonist |
Selective PPAR-delta agonist |
| Primary commercial use |
Second-line PBC |
Second-line PBC |
| Pruritus positioning |
Not established as the principal label differentiator |
Trial data support an antipruritic positioning, subject to label interpretation |
| Key risk |
Myopathy, rhabdomyolysis, fractures, fetal harm |
Liver-related monitoring and class-specific tolerability considerations |
| Competitive status |
Early commercial launch |
Direct post-launch competitor |
IQIRVO has a mechanistic distinction through dual PPAR-alpha and PPAR-delta activity. That distinction may support scientific differentiation, but physicians and payers are likely to focus on biochemical response, itch control, safety, dosing convenience, formulary placement, and real-world persistence.
When does IQIRVO lose U.S. regulatory exclusivity?
IQIRVO received FDA orphan-drug designation for PBC. Orphan-drug exclusivity generally lasts seven years from approval and prevents FDA approval of the same drug for the same disease or condition during that period, subject to statutory exceptions.
| Exclusivity category |
Relevant date or status |
| FDA approval |
June 10, 2024 |
| Accelerated approval |
Yes |
| Orphan-drug exclusivity |
Expected to run through approximately June 10, 2031 |
| Confirmatory trial requirement |
Yes |
| NCE exclusivity |
Public regulatory materials should be reviewed separately for a definitive determination |
| Pediatric exclusivity |
No publicly identified six-month extension |
| Patent expiry |
Depends on issued patent claims, terminal disclaimers, and any patent-term adjustment |
Orphan exclusivity is not the same as patent exclusivity. A generic manufacturer could potentially challenge patents before orphan exclusivity expires, but FDA approval of the same drug for the same orphan indication would remain constrained by the orphan framework. A different formulation, indication, or potentially different product presentation could create separate regulatory and patent questions.
What patents protect IQIRVO?
IQIRVO is a small-molecule product, so its intellectual-property position is likely to include composition-of-matter, polymorph, formulation, manufacturing, and method-of-use claims. The commercial value of each category is different.
| Patent category |
Relevance to IQIRVO |
| Composition of matter |
Potentially the strongest protection if an unexpired elafibranor compound claim covers the marketed active ingredient |
| Salt, crystal, or polymorph |
Can delay generic entry if the marketed form is specifically claimed |
| Formulation |
May protect dosage strength, excipients, stability, or release characteristics |
| Method of use |
May cover treatment of PBC, ALP reduction, or patient subgroups |
| Manufacturing process |
Can raise process-development costs but is usually less effective against a non-infringing alternative process |
| Combination therapy |
May cover use with UDCA or defined treatment regimens |
The FDA label and approval announcement do not establish a complete patent-expiration schedule. IQIRVO’s effective patent protection therefore cannot be reduced to a single expiration date without reviewing the current Orange Book entries, issued patent claims, patent-term adjustments, terminal disclaimers, and any listed pediatric or regulatory extensions.
The key patent question is whether an unexpired composition-of-matter claim covers elafibranor itself. If such a claim exists and remains enforceable, it would provide materially stronger protection than a method-of-use or formulation patent. Method-of-use claims can still support litigation, but they are more vulnerable to prescribing, labeling, and non-infringement strategies.
What is the Orange Book status of IQIRVO?
IQIRVO is approved under NDA 217899. FDA approval does not itself indicate how many patents are listed in the Orange Book or whether a generic applicant has filed a Paragraph IV certification.
No widely reported IQIRVO Paragraph IV litigation had emerged in the early post-launch period. That is consistent with the product’s recent approval and the relatively small commercial base available to a first generic challenger. A Paragraph IV case becomes more likely when:
- IQIRVO prescriptions and reimbursement reach a scale that supports litigation costs.
- The principal composition patent approaches expiry.
- A generic manufacturer can design around formulation or process claims.
- The orphan-exclusivity period nears expiration.
- Ipsen adds new patents covering pediatric, combination, or dosage-regimen uses.
The practical generic-entry risk is therefore low in the near term but cannot be considered remote over the full product life cycle.
What is the litigation and settlement outlook for IQIRVO?
IQIRVO has no major publicly reported U.S. patent litigation comparable to the disputes that affected older PBC products. There is also no publicly reported Paragraph IV settlement involving IQIRVO that establishes an agreed generic-entry date.
The most relevant future litigation scenarios are:
- A Paragraph IV challenge to an Orange Book-listed composition or formulation patent.
- A declaratory-judgment action concerning patent listing or claim scope.
- Litigation over an ANDA that uses a non-infringing manufacturing process.
- A dispute concerning orphan-drug exclusivity or the scope of the approved indication.
- Patent litigation over a later IQIRVO formulation or combination regimen.
The absence of early litigation is commercially favorable for Ipsen. It preserves pricing flexibility and reduces the likelihood of an early authorized-generic or settlement-driven entry event.
What licensing deal controls IQIRVO commercialization?
Ipsen obtained rights to elafibranor from Genfit under a 2021 licensing transaction. The agreement gave Ipsen global rights to develop, manufacture, and commercialize elafibranor, subject to the deal’s territorial and contractual terms. Publicly disclosed economics included a $120 million upfront payment and potential milestone payments of up to $480 million, plus tiered royalties on net sales.[3]
| Deal term |
Publicly disclosed position |
| Originator |
Genfit |
| Licensee |
Ipsen |
| Transaction year |
2021 |
| Upfront payment |
$120 million |
| Potential milestones |
Up to $480 million |
| Royalties |
Tiered royalties on net sales |
| Commercial responsibility |
Ipsen |
These economics create a variable cost structure for IQIRVO. Revenue growth will not translate one-for-one into operating profit because Ipsen must account for royalties and any remaining development or commercial milestones. The agreement also reduces Ipsen’s internal discovery risk because the asset was acquired after clinical proof of concept, but it limits the economics relative to a fully owned product.
What is IQIRVO’s financial trajectory?
IQIRVO launched into the U.S. market in the second half of 2024. Ipsen does not separately disclose IQIRVO revenue in a way that permits a complete standalone income statement. The product’s near-term financial trajectory is therefore best assessed through commercial milestones.
Launch phase: 2024 to 2025
The initial period was defined by:
- U.S. market access and payer contracting.
- Specialist education in hepatology and gastroenterology.
- Replacement demand following Ocaliva’s withdrawal.
- Competition from Livdelzi.
- Establishment of prior-authorization criteria.
- Identification of patients with inadequate UDCA response.
Early revenue was likely limited by the short launch period in 2024 and the small number of prescribers treating PBC. A launch curve based on specialty adoption is more appropriate than a mass-market launch model.
Expansion phase: 2025 to 2027
Growth depends on five variables:
| Driver |
Financial effect |
| Specialist adoption |
Determines new-patient starts |
| Persistence |
Determines recurring annual revenue |
| Formulary access |
Controls approval friction and discounts |
| Ocaliva replacement |
Creates incremental demand |
| International approvals |
Expands the addressable market beyond the U.S. |
IQIRVO can support durable revenue if physicians view it as a reliable second-line option and if Ipsen secures favorable payer placement. Its revenue ceiling is limited by the size of the diagnosed PBC population and by direct competition from Livdelzi.
Long-term phase: 2028 onward
Long-term value depends on confirmatory-trial performance and patent durability. A successful confirmatory program could convert the product from an accelerated approval to traditional approval, reduce regulatory overhang, and improve physician confidence. A failed confirmatory trial could lead to label restrictions, withdrawal, or a significant reduction in commercial value.
The product’s financial profile is therefore asymmetric: regulatory confirmation can extend the franchise and support international expansion, while failure could impair revenue before patent expiry becomes the primary issue.
What are the main generic and biosimilar risks for IQIRVO?
IQIRVO is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply. The relevant future threat is an ANDA-based generic.
Near-term generic risk is low because:
- The product was approved in 2024.
- The market is specialized.
- The commercial opportunity may not yet justify early litigation.
- Orphan exclusivity is expected to extend to approximately 2031.
- Prescribing depends on specialist diagnosis and reimbursement.
Longer-term risk increases if the core compound patent expires before or near the end of orphan exclusivity. Once generic entry occurs, price erosion could be substantial unless Ipsen has secured differentiated formulations, combination regimens, additional indications, or strong physician loyalty.
How strong is the IQIRVO competitive position?
IQIRVO has a credible but contested position in PBC.
Strengths include:
- FDA approval before Livdelzi.
- A substantial biochemical response in the pivotal trial.
- A differentiated dual PPAR mechanism.
- An established global specialty-pharma commercial platform.
- Demand created by Ocaliva’s U.S. withdrawal.
- Seven years of expected orphan exclusivity.
Weaknesses include:
- Accelerated approval and unconfirmed clinical benefit.
- Direct competition from Livdelzi.
- A limited rare-disease market.
- Safety monitoring requirements.
- Unclear standalone revenue disclosure.
- Royalty and milestone obligations to Genfit.
- Potential future generic exposure after orphan and patent protections decline.
Key Takeaways
- IQIRVO is Ipsen’s second-line oral therapy for PBC and received FDA accelerated approval on June 10, 2024.
- The product competes directly with Livdelzi and benefits from the U.S. withdrawal of Ocaliva.
- Its pivotal biochemical response was 51% versus 4% for placebo, but cross-trial comparison with Livdelzi is unreliable.
- Expected orphan-drug exclusivity runs to approximately June 2031.
- IQIRVO is a small molecule, so future competition will come from generic manufacturers rather than biosimilars.
- Ipsen acquired global elafibranor rights from Genfit for $120 million upfront, up to $480 million in milestones, and tiered royalties.
- Ipsen does not separately report IQIRVO revenue, preventing a complete standalone financial forecast.
- The principal value drivers are payer access, specialist adoption, Ocaliva replacement demand, Livdelzi competition, and confirmatory-trial success.
- No major publicly reported IQIRVO Paragraph IV litigation or settlement had emerged in the early post-launch period.
- The most important long-term risk is loss of accelerated approval or failure to demonstrate clinical benefit in confirmatory studies.
FAQs About IQIRVO Market and Patent Risk
Is IQIRVO replacing Ocaliva?
IQIRVO is one of the products positioned to capture patients who previously received Ocaliva, but it is not an automatic replacement. Physicians may select IQIRVO, Livdelzi, or other management strategies based on safety, biochemical response, pruritus, payer policy, and patient-specific factors.
Is IQIRVO a biologic drug?
No. IQIRVO contains elafibranor, a chemically synthesized small molecule. It is subject to generic-drug competition rather than biosimilar competition.
Does IQIRVO have full FDA approval?
No. IQIRVO received accelerated approval based on a biochemical surrogate endpoint. Ipsen must complete confirmatory studies intended to verify clinical benefit.
Can a generic company challenge IQIRVO before 2031?
A generic company could file a Paragraph IV certification against listed patents before orphan exclusivity expires. However, patent litigation and FDA approval timing would depend on the specific patents, certification, claim scope, and applicable exclusivity protections.
Which company owns IQIRVO?
Ipsen commercializes IQIRVO under its licensing agreement with Genfit. Genfit originated the elafibranor program and is entitled to royalties and potential milestone payments under the transaction.
References
-
U.S. Food and Drug Administration. (2024, June 10). FDA grants accelerated approval to elafibranor for primary biliary cholangitis. FDA.
-
U.S. Food and Drug Administration. (2024, August 14). FDA grants accelerated approval to seladelpar for primary biliary cholangitis. FDA.
-
Ipsen. (2021, December 13). Ipsen and Genfit enter into exclusive licensing agreement for elafibranor in primary biliary cholangitis. Ipsen.
-
U.S. Food and Drug Administration. (2024). IQIRVO (elafibranor) prescribing information. FDA.
-
Ipsen. (2025). Universal registration document and annual financial report. Ipsen.
